Skip to main content
Premium Trial:

Request an Annual Quote

Epistem's Biomarker Division Receives GCLP Accreditation

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK biotech Epistem said today its Biomarker Division has received Good Clinical Laboratory Practice accreditation status.

The company said in a statement that the accreditation allows it to support later phases of drug development, and that all studies will be conducted to meet GCLP standards established by the British Association of Research Quality Assurance.

The Biomarker Division conducts gene expression analysis for pharmaceutical and biotechnology firms aimed at new drug development. An increasing focus of the division is providing biomarkers for the development of new companion diagnostics, Epistem said.

Based in Manchester, UK, Epistem has developed a proprietary cDNA amplification technique which enables researchers to get gene expression information from very small and degraded amounts biological samples. The company also has "off-the-shelf" biomarkers targeting known cancer and disease-specific biological pathways.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.